348 related articles for article (PubMed ID: 36614089)
1. Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma.
Al-Odat OS; Guirguis DA; Schmalbach NK; Yao G; Budak-Alpdogan T; Jonnalagadda SC; Pandey MK
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614089
[TBL] [Abstract][Full Text] [Related]
2. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
Ria R; Vacca A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
[TBL] [Abstract][Full Text] [Related]
3. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
Yen CH; Hsiao HH
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
[TBL] [Abstract][Full Text] [Related]
4. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
Manni S; Carrino M; Semenzato G; Piazza F
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
[TBL] [Abstract][Full Text] [Related]
5. Autophagy and the Bone Marrow Microenvironment: A Review of Protective Factors in the Development and Maintenance of Multiple Myeloma.
Hamedi KR; Harmon KA; Goodwin RL; Arce S
Front Immunol; 2022; 13():889954. PubMed ID: 35663979
[TBL] [Abstract][Full Text] [Related]
6. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
7. Growth factors and antiapoptotic signaling pathways in multiple myeloma.
van de Donk NW; Lokhorst HM; Bloem AC
Leukemia; 2005 Dec; 19(12):2177-85. PubMed ID: 16239913
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
9. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
10. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma in the marrow: pathogenesis and treatments.
Fairfield H; Falank C; Avery L; Reagan MR
Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787
[TBL] [Abstract][Full Text] [Related]
12. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.
Liu Z; Xu J; He J; Liu H; Lin P; Wan X; Navone NM; Tong Q; Kwak LW; Orlowski RZ; Yang J
Oncotarget; 2015 Oct; 6(33):34329-41. PubMed ID: 26455377
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma.
Ikeda S; Abe F; Matsuda Y; Kitadate A; Takahashi N; Tagawa H
Cancer Sci; 2020 Nov; 111(11):4088-4101. PubMed ID: 32790954
[TBL] [Abstract][Full Text] [Related]
14. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
15. Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.
Bosman MC; Reis CR; Schuringa JJ; Vellenga E; Quax WJ
J Biol Chem; 2014 Jan; 289(2):1071-8. PubMed ID: 24280212
[TBL] [Abstract][Full Text] [Related]
16. Targeting autophagy in multiple myeloma.
Yun Z; Zhichao J; Hao Y; Ou J; Ran Y; Wen D; Qun S
Leuk Res; 2017 Aug; 59():97-104. PubMed ID: 28599191
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
Yang WC; Lin SF
Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
[TBL] [Abstract][Full Text] [Related]
18. Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma.
Chakraborty C; Mukherjee S
Curr Oncol; 2022 Dec; 29(12):9535-9549. PubMed ID: 36547163
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.
De Veirman K; Menu E; Maes K; De Beule N; De Smedt E; Maes A; Vlummens P; Fostier K; Kassambara A; Moreaux J; Van Ginderachter JA; De Bruyne E; Vanderkerken K; Van Valckenborgh E
Cancer Lett; 2019 Feb; 442():233-241. PubMed ID: 30419344
[TBL] [Abstract][Full Text] [Related]
20. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
